NCT04059367View on ClinicalTrials.gov

Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 15, 2019

Primary Completion Date

January 2, 2020

Study Completion Date

January 2, 2020

Conditions
Healthy VolunteersOverweightObesity
Interventions
DRUG

NNC9204-1177

Increasing doses of NNC9204-1177 administered s.c. (subcutaneously, under the skin) in the stomach area once-weekly for 11 weeks

DRUG

Cocktail of 5 already approved drugs

5 medicines as tablets, capsules or syrup to be taken with water on Day 1 and Day 78 of the study

Trial Locations (1)

78209

Novo Nordisk Investigational Site, San Antonio

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY